A supplemental application for Keytruda (pembrolizumab) received FDA approval for efficacy on July 1, 2021. This approval indicates an expansion of the drug's approved uses based on demonstrated effectiveness.
Background
Pembrolizumab, marketed as Keytruda, is a widely recognized therapeutic agent. This specific approval pertains to a supplemental application, categorized under "Efficacy," meaning it adds a new indication or patient population to the drug's label. The sponsor for Keytruda is MERCK SHARP DOHME.
What this means
The FDA's approval of this supplemental application for Keytruda (pembrolizumab) signifies that the drug has demonstrated efficacy for an additional indication or in a new patient population. This expands the available treatment options for clinicians and patients, allowing for the use of Keytruda in a broader context than previously approved. While the specific details of the new indication are not provided in this update, the approval confirms a positive assessment of the drug's benefits in the new therapeutic area.
Source
The information regarding this supplemental FDA approval for Keytruda (pembrolizumab) was obtained from the FDA. The approval of the supplemental application (BLA 125514 S-100) for efficacy was granted on July 1, 2021, and is publicly accessible on accessdata.fda.gov.